REPROCELL Expands Clinical iPSC and Stem Cell Solutions in China Through Strategic Collaboration with WEIPU Biotechnology

Yokohama, Japan / Suzhou, China – July 27, 2026 – REPROCELL Inc., a global provider of clinical-grade iPSC technologies and regenerative medicine solutions, today announced a strategic collaboration with WEIPU Biotechnology Co., Ltd., a biotechnology company based in Suzhou, China, to support cell therapy developers in China with access to high-quality clinical starting materials and complementary biological testing services.

Through this collaboration, REPROCELL will provide cell therapy developers with access to its StemRNA™ Clinical iPSC technologies and iPSC-derived mesenchymal stem cell (iMSC) seed and master cell banks. These clinical-grade starting materials are supported by comprehensive quality documentation and characterization programs designed to align with global regulatory expectations, including requirements established by the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and Japan Pharmaceuticals and Medical Devices Agency (PMDA).

These well-characterized iPSC and iMSC starting materials enable developers to establish robust cell sources for research, development, and future clinical applications.

This collaboration also encompasses the introduction of REPROCELL’s StemEdit clinical gene-editing services in China. Leveraging REPROCELL’s proprietary clinical gene-editing technology and newly developed gene-edited iPSC lines, which are available for immediate use, the collaboration provides a GMP-aligned, traceable, and regulatory-ready platform to support downstream clinical applications. The StemEdit technology enables the production of StemRNA™ Clinical iPSC lines with B2M/CIITA double-knockout (KO) gene editing for clinical use.

As part of the collaboration, WEIPU Biotechnology will provide biological services, biosafety testing, and cell bank characterization support for organizations using REPROCELL-derived cell materials in advanced therapy development programs. These services will support quality evaluation and safety assessment requirements for programs requiring comprehensive characterization packages.

The collaboration will support biotechnology companies, pharmaceutical organizations, and research institutions developing cell-based therapies that require globally aligned starting materials and reliable testing solutions to advance their development programs.

“We are committed to enabling cell therapy developers worldwide with access to high-quality clinical starting materials supported by robust characterization and documentation,” said Dr Chikafumi Yokoyama, CEO at REPROCELL. “China represents an important and rapidly growing market for regenerative medicine innovation, and our collaboration with WEIPU Biotechnology enables regional developers to access globally aligned stem cell materials together with complementary biological testing support.” said Dr Sarah Eminli-Meissner, Head of Business, Stem Cells at REPROCELL.

“Developers of advanced therapies increasingly require access to high-quality starting materials supported by comprehensive biological services and safety testing solutions that meet global development expectations,” said Jenna Yang, CEO/Chief Scientist at WEIPU Biotechnology. “Through our collaboration with REPROCELL, we will support customers with biological services, biosafety testing, and cell bank characterization capabilities that complement REPROCELL’s clinical-grade stem cell technologies.”

This strategic collaboration represents an important step in REPROCELL’s continued global expansion and commitment to supporting cell therapy developers with reliable access to clinical-grade starting materials, comprehensive testing capabilities, and regional technical support.

About StemRNA™ Clinical iPSC

StemRNA™ Clinical Seed iPSC clones are clinical-grade induced pluripotent stem cell (iPSC) lines generated using REPROCELL's proprietary non-integrating RNA reprogramming technology and manufactured in accordance with regulatory standards relevant to the FDA, EMA, and PMDA. These cell lines provide high-quality starting material for biotechnology and pharmaceutical companies developing regenerative medicine and cell therapy products. Multiple donor-derived clones are available as off-the-shelf options, and customized, exclusive iPSC lines can also be generated to meet specific program requirements.

About StemEdit Clinical Gene-editing

StemEdit encompasses REPROCELL’s proprietary clinical gene-editing technology and its new gene-edited iPSC lines that are ready for immediate use, ensuring a GMP-aligned, traceable, and regulatory-ready platform from the outset. StemEdit is designed to support allogeneic off-the-shelf cell therapy development, offering enhanced targeting flexibility, improved safety profiles, and licensing-friendly alternatives to heavily encumbered CRISPR-Cas systems.

About REPROCELL

REPROCELL provides integrated stem cell, gene editing, and drug discovery services supporting programs from discovery through clinical development. Headquartered in Yokohama, Japan, with global operations in the United States, Europe, and Asia, REPROCELL partners with academic, biotechnology, and pharmaceutical organizations worldwide to advance regenerative medicine and cell therapy development.

Website: www.REPROCELL.com

About WEIPU Biotechnology Co., Ltd.

WEIPU Biotechnology Co., Ltd. is a biotechnology company based in Suzhou, China, providing biological services, biosafety testing, and cell bank characterization solutions for biotechnology, pharmaceutical, and cell therapy developers worldwide.

Featuring an 8,000 square meter biosafety laboratory accredited with EU QP, BSL 2, ABSL 2, ISO 9001, CMA, CNAS and animal experiment licenses, WEIPU delivers comprehensive solutions to biopharmaceutical R&D companies that comply with regulatory requirements of China, the US and Europe.

Website: www.weipubio-tech.com/en/